logo-loader
viewMotif Bio PLC

Phase III Iclaprim trial results 'bode very well' for Motif Bio, says Northland Capital's Alexandre

Vadim Alexandre, head of research at Northland Capital Partners gives his view on Motif Bio Plc's (LON: MTFB, NASDAQ:MTFB) successful completion of a phase III clinical trial of its next-generation antibiotic, iclaprim.

The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections (ABSSSI).

''We know [Iclaprim] kills bacteria in the petri dish, we now know from this trial that it works in humans and we also know from a previous phase III trial ...  that it met its primary endpoint as well'', Alexandre says.

''There's very good reason to believe that the drug works and there's nothing in these results that are red flags to say that it shouldn't work in the second trial''.

Quick facts: Motif Bio PLC

Price: 0.068 GBX

AIM:MTFB
Market: AIM
Market Cap: £330.04 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Primary Health Properties 'in robust shape' and playing its part in fight...

Primary Health Properties PLC's  (LON:PHP) Harry Hyman and Richard Howell tell Proactive London's Andrew Scott they're working with health authorities to utilise its properties better during the current coronavirus crisis. They add that all of its rents are effectively guaranteed by the...

13 hours, 5 minutes ago

2 min read